Table 10.

Pharmacokinetics of designed 2-(4-fluorophenyl) imidazole-5-ones compounds

S/No.	MW (mg/mol)	nAH	nRB	HBA	HBD	MR	TPSA (Å2)	iLOGP	BBB	PAIN	Brenk
1	415.24	17	3	4	0	114.8	45.81	3.81	Yes	1	2
2	415.24	17	3	4	0	114.8	3.72	3.72	Yes	1	2
3	504.15	17	3	4	0	120.18	45.81	3.93	Yes	1	1
4	382.34	17	3	6	0	104.69	45.81	3.52	Yes	1	1
5	415.24	17	3	4	0	114.80	45.81	3.70	Yes	1	1
6	415.24	17	3	4	0	114.80	45.81	3.72	Yes	1	2
7	504.15	17	3	4	0	120.18	45.81	3.80	Yes	1	2
8	490.12	17	3	4	0	115.21	45.81	3.51	Yes	1	1
9	401.22	17	3	4	0	109.83	45.81	3.49	Yes	1	2
10	490.12	17	3	4	0	115.21	45.81	3.51	Yes	1	1
11	490.12	17	3	4	0	115.21	45.81	3.74	Yes	1	2
12	401.22	17	3	4	0	109.83	45.81	3.35	Yes	1	1
13	490.12	17	3	4	0	115.21	45.81	3.70	Yes	1	2
14	401.22	17	3	4	0	109.83	45.81	3.49	Yes	1	2
15	472.25	17	3	4	0	117.49	45.81	3.67	Yes	1	2
16	425.25	17	3	4	0	112.48	45.81	3.76	Yes	1	1
17	380.80	17	3	4	0	109.79	45.81	3.72	Yes	1	1
18	366.77	17	3	4	0	104.82	45.81	3.29	Yes	1	1

MW Molecular weight (<500 mg/mol), nAH number of aromatic heavy atoms, nRB rotatable bonds, HBA Hydrogen bond acceptors, HBD Hydrogen bond donors, MR molecular refractivity, TPSA Topological polar surface area, BBB blood-brain barrier